Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

188.15USD
22 Jan 2018
Change (% chg)

$6.82 (+3.76%)
Prev Close
$181.33
Open
$181.00
Day's High
$188.42
Day's Low
$181.00
Volume
1,153,406
Avg. Vol
680,568
52-wk High
$256.78
52-wk Low
$160.09

Latest Key Developments (Source: Significant Developments)

Allergan PLC Reports 6.8 Pct Stake In Teva Pharmaceutical Industries As Of January 10, 2018
Friday, 12 Jan 2018 06:17am EST 

Jan 12 (Reuters) - Allergan Plc ::ALLERGAN PLC REPORTS 6.8 PERCENT STAKE IN TEVA PHARMACEUTICAL INDUSTRIES LTD AS OF JANUARY 10, 2018 - SEC FILING‍​.ALLERGAN PLC HAD EARLIER REPORTED 9.9 PERCENT STAKE IN TEVA PHARMACEUTICAL INDUSTRIES LTD AS OF NOVEMBER 10, 2017 - SEC FILING‍​.  Full Article

‍Pershing Square announces management fee reduction related to Allergan settlement​
Tuesday, 9 Jan 2018 11:19pm EST 

Jan 9 (Reuters) - Pershing Square Holdings Ltd ::‍PERSHING SQUARE HOLDINGS, LTD. ANNOUNCES MANAGEMENT FEE REDUCTION RELATED TO ALLERGAN SETTLEMENT.‍SUBSTANTIALLY ALL OF LEGAL FEES RELATED TO ALLERGAN MATTER HAVE BEEN COVERED BY INSURANCE.‍ASSUMING SETTLEMENT FINALIZED BY COURT, WILL BE REDUCING MANAGEMENT FEES FOR ALL OF PERSHING SQUARE FUNDS WHICH INCURRED LITIGATION EXPENSE BY TOTAL OF $32.2 MLN.‍FEE REDUCTION WILL BE REALIZED IN EIGHT INSTALLMENTS OVER NEXT 8 QUARTERS BEGINNING WITH MANAGEMENT FEE PAYABLE ON APRIL 1, 2018.‍REDUCTION IN MANAGEMENT FEES NOT SIMPLY TIMING BENEFIT FOR INVESTORS AS EXISTING YEAR-END 2017 HIGH WATER MARKS WILL REMAIN UNCHANGED​​​.  Full Article

Allergan Provides Preliminary 2018 Outlook, Update On Teva Holding
Monday, 8 Jan 2018 04:30pm EST 

Jan 8 (Reuters) - Allergan Plc ::ALLERGAN PROVIDES 2018 PRELIMINARY FINANCIAL OUTLOOK FOR SELECT INCOME STATEMENT CATEGORIES AND OTHER UPDATES.SEES 2018 GAAP NET REVENUE OF ABOUT $15 BILLION - $15.3 BILLION.SEES 2018 GAAP PERFORMANCE LOSS PER SHARE $0.84; SEES 2018 NON-GAAP PERFORMANCE EARNINGS PER SHARE GREATER THAN OR EQUAL TO $15.25.FY2018 EARNINGS PER SHARE VIEW $15.80, REVENUE VIEW $15.61 BILLION -- THOMSON REUTERS I/B/E/S.SEES NO GENERIC ENTRY FOR RESTASIS PRIOR TO Q2 2018.SEES ONGOING COST REDUCTIONS OF $300 MILLION – $400 MILLION IN 2018 FROM FISCAL 2017 NON-GAAP OPERATING EXPENSES.ANTICIPATES FUTURE IMPACT OF TAX CUT AND JOBS ACT TO BE BROADLY NEUTRAL TO CO'S NON-GAAP EFFECTIVE TAX RATE OVER TIME.CONTINUES TO "PRUDENTLY DIVEST" ITS REMAINING HOLDING IN SECURITIES OF TEVA.PLANS TO SELL REMAINING POSITION IN TEVA IN 2018 THROUGH FORWARD SALE AGREEMENTS AND/OR OPEN MARKET SALES.SAYS "WE FACE LOSS OF EXCLUSIVITY REVENUE HEADWINDS IN 2018".  Full Article

Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017
Monday, 8 Jan 2018 11:51am EST 

Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017.IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​.IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017.IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017.  Full Article

Allergan Says In Connection With Internal Reorganization, Forest Laboratories Merged With And Into Allergan Sales
Tuesday, 2 Jan 2018 04:31pm EST 

Jan 2 (Reuters) - Allergan Plc ::ALLERGAN SAYS IN CONNECTION WITH INTERNAL REORGANIZATION, FOREST LABORATORIES LLC MERGED WITH AND INTO ALLERGAN SALES LLC- SEC FILING.  Full Article

Allergan Acknowledges Appeals Court Decision For Combigan
Friday, 22 Dec 2017 02:45pm EST 

Dec 22 (Reuters) - Allergan Plc ::ALLERGAN ACKNOWLEDGES APPEALS COURT DECISION FOR COMBIGAN®.SAYS ‍CO EXPECTS TO FILE PETITIONS FOR REHEARING AND/OR REHEARING EN BANC OF APPEALS COURT DECISION WITHIN 30 DAYS​.ALLERGAN - DOESN'T BELIEVE COURT'S INJUNCTION PREVENTING FINAL APPROVAL, LAUNCH OF SANDOZ PRODUCT WILL BE LIFTED PRIOR TO DECISION ON CO'S PETITIONS.ALLERGAN - APPEALS COURT RULING WILL NOT RESULT IN MARKET FORMATION FOR GENERIC COMBIGAN PRODUCT.  Full Article

FDA Accepts New Drug Application For Seysara (Sarecycline)
Wednesday, 20 Dec 2017 04:30pm EST 

Dec 20 (Reuters) - Allergan Plc ::FDA ACCEPTS NEW DRUG APPLICATION FOR SEYSARA™ (SARECYCLINE) FOR THE TREATMENT OF MODERATE TO SEVERE ACNE.PARATEK PHARMACEUTICALS INC - ALLERGAN EXPECTS PRESCRIPTION DRUG USER FEE ACT ACTION DATE TO OCCUR IN SECOND HALF OF 2018.  Full Article

Allergan And Richter Announce Positive Topline Results From Phase 3 Study Of Cariprazine For Treatment Of Bipolar I Depression
Monday, 18 Dec 2017 08:00am EST 

Dec 18 (Reuters) - Allergan Plc ::ALLERGAN AND RICHTER ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF CARIPRAZINE FOR THE TREATMENT OF BIPOLAR I DEPRESSION.ALLERGAN PLC - IN THE STUDY, PRIMARY EFFICACY OBJECTIVE WAS MET FOR BOTH CARIPRAZINE 1.5MG AND 3MG DOSE GROUPS.ALLERGAN PLC - PLANS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION IN 2ND HALF OF 2018.  Full Article

‍GIC Private reports a 5.11 pct passive stake in Allergan ​
Thursday, 16 Nov 2017 04:39pm EST 

Nov 16 (Reuters) - Allergan Plc :As of Nov 8, ‍GIC Private reports a 5.11 pct passive stake in - SEC filing ​.  Full Article

Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia
Monday, 13 Nov 2017 07:35am EST 

Nov 13 (Reuters) - Allergan Plc :Allergan receives FDA approval for use of Vraylar (cariprazine) in the maintenance treatment of schizophrenia.Allergan - ‍Vraylar is approved in U.S. in adults for acute treatment of schizophrenia & acute treatment of manic/ mixed episodes of bipolar I disorder​.  Full Article

Allergan loses bid to avoid Asacol antitrust trial after appellate order

Allergan PLC on Friday lost a last-minute bid to delay an upcoming trial in a class action lawsuit claiming it suppressed generic competition for its ulcerative colitis drug Asacol.